Q4 FY2025 · ended Dec 31, 2025 · Revenue $-11.14M, -592.6% YoY · Filed Mar 17, 2026
Capricor Therapeutics, Inc. (CAPR) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$35.5 million. As of Jun 30, 2026 it held $237.9 million in cash and investments and $91.0 million in total debt.
Revenue
$-11.14M
-592.6% vs prior quarter
Net income
$-40.73M
-57.2% vs year-ago quarter
Operating cash flow
$-31.49M
-56.5% vs year-ago quarter
Free cash flow
$-35.55M
-74.2% vs year-ago quarter
EPS
$-0.70
-22.8% vs year-ago quarter
Dividend per share
None
Shares outstanding
58.14M
+27.2% vs year-ago quarter
Net cash
$146.89M
Q2 FY2026
Operating margin
261.7%
Q4 FY2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CAPR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1133869
- Former names
- Nile Therapeutics, Inc. (until Nov 20, 2013); SMI PRODUCTS INC (until Sep 19, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | -$11.1M | — | — |
| Operating income | -$42.9M | -$36.8M | -$29.2M | -$26.3M | -$27.7M |
| Net income | -$40.7M | -$33.9M | -$30.2M | -$24.6M | -$25.9M |
| Diluted EPS | -$0.70 | -$0.59 | -$0.62 | -$0.54 | -$0.57 |
| Operating cash flow | -$31.5M | -$29.3M | -$23.6M | -$19.7M | -$20.1M |
| Free cash flow | -$35.5M | -$34.4M | -$25.2M | -$19.7M | -$20.4M |
| Total assets | $368.7M | $326.3M | $355.9M | $126.4M | $133.6M |
| Total liabilities | $122.5M | $47.6M | $50.2M | $42.6M | $28.6M |
| Stockholders' equity | $246.2M | $278.7M | $305.8M | $83.9M | $105.0M |
| Cash and investments | $237.9M | $278.6M | $318.1M | $98.6M | $122.8M |
| Total debt | $91.0M | $14.8M | $14.5M | $14.5M | $1.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Aug 24, 2026 | Aug 24, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Other events
|
Jul 30, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Other events
|
Jul 29, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Jul 14, 2026 | Jul 9, 2026 |
All 963 Capricor Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.